| 1. |
簡鋼仁, 鄭若菲, 葉誠棟. 標準化作業程序在移動方艙醫院全面快速展開的應用研究. 中華災害救援醫學, 2019, 7(10): 551-554.
|
| 2. |
王當瑞, 馬友才, 王春香, 等. 武漢方艙醫院問題分析及未來方艙建設思考. 建筑節能, 2021, 9(49): 166-170.
|
| 3. |
國家衛生健康委辦公廳. 《新型冠狀病毒肺炎診療方案》(試行第九版).2022-03-14.
|
| 4. |
劉俊峰, 翟曉輝, 向準, 等. 應對新型冠狀病毒肺炎疫情的方艙醫院建設管理探討. 中國醫院管理, 2020, 3(40): 12-14.
|
| 5. |
中國疾病預防控制中心. 新型冠狀病毒肺炎應急響應機制流行病學組. 新型冠狀病毒肺炎流行病學特征分析. 中華流行病學雜志, 2020, 41(2): 145-151.
|
| 6. |
Zhao YL, Nan YD, Jin FG. Role of angiotensin-converting enzyme (ACE) and ACE2 in a rat model of smoke inhalation induced acute respiratory distress syndrome. Burns, 2015, 41(7): 1468-1477.
|
| 7. |
Pinto BG, Oliveira AE, Singh Y, et al. ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19. J Infect Dis, 2020, 222(4): 556-563.
|
| 8. |
Guisado-Vasco P, Valderas-Ortega S, MM Carralon-Gonzalez, et al. Clinical characteristics and outcomes among hospitalized adults withsevere COVID-19 admitted to a tertiary medical center and receivingantiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort). E Clinical Medicine, 2020, 28: 100591.
|
| 9. |
Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus infected pneumonia in Wuhan, China. JAMA, 2020, 323(11): 1061-1069.
|
| 10. |
李殿明, 劉傳苗, 劉佳慧, 等. 普通型向重型演變的新型冠狀病毒肺炎病人的危險因素分析. 蚌埠醫學院學報, 2020, 45(4): 21-424.
|
| 11. |
Cilloniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in communityacquired pneumonia. Chest, 2013, 144(3): 999-1007.
|
| 12. |
王陽春, 仝瑞祥, 劉飛, 等. 糖尿病患者易感新型冠狀病毒的免疫因素分析. 中國糖尿病雜志, 2020, 28(3): 176-179.
|
| 13. |
趙茜, 曹相原, 劉伶俐, 等. 新型冠狀病毒肺炎合并糖尿病患者精細化管理效果分析. 現代醫院, 2020, 20(12): 1841-1844.
|
| 14. |
戴志輝, 高立冬, 羅塏煒, 等. 湖南省新型冠狀病毒肺炎臨床特征分析. 實用預防醫學, 2020, 4(27): 396-399.
|
| 15. |
潘月影, 王玉錦, 祝婷婷, 等. 938 例老年新型冠狀病毒肺炎患者 影像學表現. 放射學實踐, 2020, 35(3): 269-271.
|
| 16. |
Halfmann PJ, Iida S, Maemura T, et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature, 2022, 603(7902): 687-692.
|
| 17. |
Suzuki R, Yamasoba D, Kimura I, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B. 1. 1. 529 Omicron. Nature, 2022, 603(7902): 693-699.
|
| 18. |
劉昌孝, 伊秀林, 崔濤, 等. 新型冠狀病毒疫苗研發與評價. 藥物評價研究, 2020, 43(7): 1421-1432.
|
| 19. |
Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China. Vaccines, 2020, 8(3): 378-342.
|
| 20. |
趙春艷, 石晶, 張國峰, 等. 北京通州區中小學生家長為子女接種新冠疫苗意愿及影響因素. 中國學校衛生, 2021, 3(42): 371-380.
|